Boost For Brain Cancer As Tocagen Enters EMA’s PRIME

 
• By Neena Brizmohun

Brain tumors now equal lymphoma as the most common type of cancers being targeted by oncology products on the European Medicines Agency’s priority medicines (PRIME) scheme for getting medicines for unmet medical needs to patents faster.

Tumour
Tocagen's drug for glioma is now on the PRIME scheme • Source: Shutterstock

More from Market Access

More from Pink Sheet